Vaccinex Inc represents values of innovation, dedication, and patient-centricity. With a strong corporate philosophy focused on advancing novel therapies, Vaccinex is committed to transforming the treatment landscape for diseases with high unmet medical needs. The company prioritizes the development of its proprietary pipeline, leveraging its unique ActivmAb® antibody discovery platform. Vaccinex aims to bring forth groundbreaking solutions that address diseases such as cancer and neurodegenerative disorders. By combining cutting-edge technology, scientific expertise, and a patient-centered approach, Vaccinex Inc aims to improve outcomes and make a significant impact in the lives of patients worldwide.

Vaccinex Inc is primarily present in the United States.

Vaccinex Inc has achieved several significant milestones in its history. Notably, the company successfully completed a Phase 2 clinical trial for its lead product candidate, pepinemab, in patients with Huntington's disease, demonstrating positive efficacy and safety outcomes. Additionally, Vaccinex Inc has secured strategic partnerships and collaborations with renowned pharmaceutical companies, enhancing its research and development capabilities. The company has also been granted various patents for its innovative antibody discovery platform, ActivMab®, further solidifying its intellectual property portfolio. These achievements highlight Vaccinex Inc's commitment to advancing novel therapeutic solutions and its potential for future growth and success.

Vaccinex Inc is a pharmaceutical company based in Rochester, New York. Established in 2001, it specializes in the development of targeted biotherapeutics to treat cancer and neurodegenerative diseases. Vaccinex's proprietary technology, known as ActivMAb, allows for the discovery and optimization of monoclonal antibody drugs. Over the years, the company has successfully advanced multiple clinical-stage programs, including its lead candidate, pepinemab, for the treatment of Huntington's disease and non-small cell lung cancer. Vaccinex continues to forge strategic partnerships and collaborations to accelerate the development and commercialization of its innovative therapies.

The main competitors of Vaccinex Inc in the market include other biotechnology companies specializing in the development of innovative therapies. With its focus on discovering and developing antibody-based therapies, Vaccinex faces competition from companies such as Genmab, Incyte Corporation, and Regeneron Pharmaceuticals. These competitors also leverage cutting-edge technologies to produce novel therapeutics for various diseases and conditions. Vaccinex Inc differentiates itself through its unique antibody discovery platform, which enables the identification of potential drug candidates with high precision and specificity. Its strong pipeline and strategic collaborations position the company well among its rivals in the biotechnology sector.

Vaccinex Inc is primarily active in the biotechnology and pharmaceutical industries.

The business model of Vaccinex Inc revolves around the development and commercialization of novel antibody-based therapeutics. The company leverages its proprietary ActivMAb platform to discover and optimize antibodies that target specific diseases, including cancer and neurodegenerative disorders. Vaccinex Inc collaborates with partners in the biopharmaceutical industry and academia to advance its pipeline and bring innovative treatments to patients. By focusing on the development of immunotherapies, Vaccinex Inc aims to address unmet medical needs and improve patient outcomes. With a strong emphasis on research and development, the company strives to create value for shareholders and stakeholders in the healthcare sector.

Pomer Vaccinex cena/zisk je 0.

Koeficient Vaccinex P/S je 0,00.

AlleAktien kvalitatívne skóre pre Vaccinex je 4/10.

Tržby spoločnosti očakávaná Vaccinex sú 26,74 mld. USD.

Zisk momentálne nie je možné vypočítať pre Vaccinex.

Vaccinex Inc is a biotechnology company focused on developing innovative treatments for cancer and neurodegenerative diseases. They have two main areas of focus: antibody development and small molecule development. The antibody program aims to develop monoclonal antibodies that specifically bind to target molecules in the body to modulate or block their functions. Vaccinex uses their proprietary technology, the ActivMAb® system, to efficiently and quickly produce and select antibodies. They combine ActivMAb® with bioinformatics tools to develop targeted antibodies for difficult-to-treat diseases. Their first product, HuMax-IL8, has reached phase 2 of clinical trials and is being used as a potential cancer therapy. They also have other projects in the preclinical phase, focusing on the treatment of Parkinson's, Alzheimer's, and other neurodegenerative diseases. The small molecule development focuses on developing drugs containing small molecules that can modulate cellular processes. The focus is on enzymes that play a crucial role in cancer development. Through targeted design and screening of molecules, potential drug candidates are identified and their efficacy and safety are tested in early clinical studies. Vaccinex has already initiated several such projects and collaborates with well-known pharmaceutical companies. Overall, Vaccinex's business model is centered around using their proprietary technologies and expertise in antibody and small molecule research to develop innovative therapeutics. They not only develop their own pipeline products but also enter into partnerships with other pharmaceutical companies and grant licenses. The focus on cancer and neurodegenerative diseases promises significant growth potential, along with a clear medical need. In summary, Vaccinex develops, licenses, and distributes innovative therapeutics in the fields of cancer and neurodegenerative diseases. Their antibody and small molecule research allows for the targeted development of drugs that can modulate or block cellular processes and influence the function of disease proteins. The company collaborates with reputable partners in the pharmaceutical industry and has a proprietary technology that efficiently and quickly leads to the discovery and selection of antibodies and drug candidates. The business model promises high growth potential by focusing on areas with significant medical need.

Vaccinex vypláca dividendu vo výške 0 USD rozdelenú do výplat počas roka.

Dividenda pre Vaccinex sa aktuálne nedá vypočítať alebo spoločnosť nevypláca dividendu.

ISIN spoločnosti Vaccinex je US9186401033.

WKN spoločnosti Vaccinex je A2N30M.

Ticker spoločnosti Vaccinex je VCNX.

V posledných 12 mesiacoch spoločnosť Vaccinex vyplatila dividendu vo výške . To zodpovedá dividendovému výnosu približne . Pre nadchádzajúcich 12 mesiacov bude pravdepodobne spoločnosť Vaccinex vyplácať dividendu 0 USD.

Súčasný výnos z dividend spoločnosti Vaccinex je .

Vaccinex vypláca dividendu každý štvrťrok. Tá je vyplácaná v mesiacoch .

Vaccinex platil každý rok počas posledných 0 rokov dividendu.

Na nasledujúcich 12 mesiacov sa očakávajú dividendy vo výške 0 USD. To zodpovedá dividendovému výnosu 0 %.

Vaccinex je priradený sektoru 'Zdravie'.

Aby ste obdržali poslednú dividendu vo výške 0 USD od Vaccinex z dňa 5. 10. 2024, museli ste mať akciu v depozite pred ex-dňom 5. 10. 2024.

Posledná dividenda bola vyplatená 5. 10. 2024.

V roku 2023 boli od Vaccinex 0 USD vyplatené ako dividendy.

Dividendy spoločnosti Vaccinex sú vyplácané v USD.